Progenics Pharmaceuticals, Inc. PGNX today announced its results of operations for the fourth quarter ended December 31, 2010.
Net loss for the fourth quarter was $18.8 million or $0.57, basic and diluted, per share, compared to $0.6 million or $0.02, basic and diluted, per share in the fourth quarter of 2009.
Fourth quarter revenue totaled $2.2 million, compared to $17.2 million for the same period of 2009, reflecting a decrease in reimbursement revenue from Wyeth, now a Pfizer, Inc. PFE subsidiary, resulting from the transition of the Progenics-Wyeth collaboration for RELISTOR®, Progenics' drug approved for the treatment of opioid-induced constipation in advanced-illness patients.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.